64/100B39.440
USD
-0.54
(-1.35%)
Market Closed
Last updated: · Delayed 15 min
Arincen ScoreWhat is the Arincen Score? The Arincen Score grades a company out of 100 from 30 checks on its own reported figures, five checks in each of six parts.Beta
64/100
Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.
Profitability5
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Cash6.7
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Valuation10
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Growth—
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Financial strength4
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Shareholders—
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Figures to FY2025; the price as of today.
Medline key facts
- StyleWhat does a stock's style mean? The style label sorts a stock as growth, value, dividend, blend or speculative, with a 1 to 10 meter showing how strongly it fits.
- Blend stock · 4.1/10Value 4.1
- Day range
- 38.960 – 40.530
- 52-week range
- 31.370 – 50.880
- Market capitalizationWhat is market capitalization? Market cap is what the stock market values a whole company at: its share price times the number of its shares outstanding.
- 34.65B USD
- P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 58.87
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 8.13
- EPSWhat is EPS (earnings per share)? EPS (earnings per share) is a company's net income divided by its number of shares: the profit that belongs to each share over a period.
- 0.67
- Volume
- 327,736
- BetaWhat is beta in stocks? Beta measures how much a stock tends to move when the whole market moves: 1 moves with it, under 1 is calmer, over 1 swings more.
- -0.39
- ESG scoreWhat is an ESG score? An ESG score rates how a company handles the environment, its people and its governance, out of 100. Higher is better.
- 62.0/100Environment 52 · Social 70 · Governance 64
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- James Boyle
- Employees
- 45K
- Website
- medline.com
- IPO date
- 17 Dec 2025
Medline earningsWhat is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
Next earnings · Q4 FY2026
EPS estimate
0.39 USD
Revenue estimate
8.50B USD
Last quarter · Q3 FY2026
EPS0.44Beat +28.2%Revenue7.86BBeat +1.7%
Revenue
ReportedEstimate
EPS
ReportedEstimate
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| Q3 FY2027 | 0.40 | — | — | -9.15% | 8.49B | — | — | +8.04% | |
| Q2 FY2027 | 0.38 | — | — | -23.46% | 8.33B | — | — | +8.36% | |
| Q1 FY2027 | 0.34 | — | — | +3.95% | 7.88B | — | — | +7.21% | |
| Q4 FY2026 | 0.39 | — | — | +73.56% | 8.50B | — | — | +9.14% | |
| Q3 FY2026 | 0.34 | 0.44 | +28.21% | +41.94% | 7.72B | 7.86B | +1.74% | +10.41% | |
| Q2 FY2026 | 0.35 | 0.50 | +41.88% | — | 7.52B | 7.69B | +2.21% | — | |
| Q1 FY2026 | 0.30 | 0.33 | +11.79% | — | 7.16B | 7.35B | +2.64% | — | |
| Q4 FY2025 | 0.24 | 0.22 | -5.63% | — | 7.51B | 7.79B | +3.66% | — | |
| Q3 FY2025 | — | 0.31 | — | — | — | 7.12B | — | — |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2027 | 1.55 | — | — | +0.60% | 33.92B | — | — | +8.07% |
| FY2026 | 1.54 | — | — | +28.20% | 31.39B | — | — | +11.47% |
| FY2025 | 1.20 | — | — | — | 28.16B | — | — | — |
Analysts' estimates for FY2025 over the last 7 days:EPS Revenue How the estimates moved
Medline analyst forecastWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
12-month price target
44.20 USD
+12.07%
Analysts' 1-year price targets range from 37.00 to 55.00, with an average of 44.20.
Past year
1-year forecast
Strong sellStrong buy
Strong buy
19 ratings
| Buy | 17 | |
| Hold | 2 | |
| Sell | 0 |
12-month price target
| Highest target | 55.00 |
| Average target | 44.20 |
| Lowest target | 37.00 |
| Current price | 39.44 |
Medline valuationWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 58.87
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 25.58
- Price to sales (TTM)What is the P/S ratio? The price-to-sales ratio compares a company's market value with its revenue over the last year: what you pay for each dollar of sales.
- 1.13
- Price to bookWhat is the P/B ratio? The price-to-book ratio compares a company's market value with its book value, the shareholders' equity on its balance sheet.
- 2.94
- EV / EBITDA (TTM)What is EV/EBITDA? EV/EBITDA compares a company's whole value, debt included and cash taken off, with a year of its earnings before interest, tax and depreciation.
- 17.00
Capital structureWhat is enterprise value? Enterprise value is what the whole business costs: the market value of its shares plus its debt minus its cash. It is the price behind EV/EBITDA.
Market capitalization
34.65B USD
+
Total debt
12.58B USD
−
Cash and short-term investments
3.61B USD
=
Enterprise value
43.63B USD
Valuation over time
P/EForward P/EForward P/E · EstimateEstimate
Medline against its own historyWhat does "against its own history" show? The company's latest margins, return on equity, growth, debt and P/E against its own last 5 years: the low, the median and the high, and whether this year is better or worse than usual.
Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: ResMed, West Pharmaceutical Services, Becton, Dickinson and, Solventum, Baxter International, and The Cooper Companies, the US Medical - Instruments & Supplies companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- Gross marginHighest in 5 years26.4%21.2%26.4%Against its peers: 7 of 7Peers' median 50.4%
- Operating marginAbove its median7.8%4.1%8.4%Against its peers: 6 of 7Peers' median 18.4%
- Net marginAbove its median4.1%-0.1%4.7%Against its peers: 6 of 7Peers' median 12.6%
- Return on equityHighest in 5 years10.8%1.4%10.8%Against its peers: 4 of 7Peers' median 10.0%
- Free cash flow marginBelow its median4.6%-0.3%6.1%Against its peers: 5 of 7Peers' median 12.8%
- Revenue growthHighest in 5 years11.5%8.3%11.5%Against its peers: 1 of 7Peers' median 5.4%
- Debt to EBITDAAt its median5.56×4.78×6.50×Against its peers: 6 of 7Peers' median 2.31×
- Current ratioHighest in 5 years4.293.394.29Against its peers: 2 of 7Peers' median 2.67
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
Medline growth and profitabilityWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- Revenue (TTM)What does TTM (trailing twelve months) mean? TTM (trailing twelve months) is a figure over the latest twelve months of reports: usually the last four quarters added together.
- 30.68B USD
- Net income (TTM)What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
- 564.00M USD
- Gross marginWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- 25.16%
- Operating margin
- 5.68%
- Net margin
- 1.84%
Revenue / Net income
Revenue Net income Net margin
How Medline makes its moneyWhat is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
Revenue28.43B 100.0%
Cost of revenue20.91B 73.6%
Gross profit7.52B 26.4%
Selling and administration4.52B 15.9%
Other operating expenses782.00M 2.8%
Operating income2.21B 7.8%
Tax91.00M 0.3%
Other expense962.00M 3.4%
Net income1.16B 4.1%
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
Medline financial health
- Cash and short-term investments
- 3.61B USD
- Total debt
- 12.58B USD
- Net cash
- -8.97B USD
- Free cash flow (TTM)What is free cash flow (FCF)? Free cash flow is the cash a company's operations bring in minus what it spends on long-term assets (capex): cash left for debt, dividends and buybacks.
- 1.90B USD
- Current ratioWhat is the current ratio? The current ratio is current assets divided by current liabilities: whether what a company will turn into cash within a year covers what it owes within a year.
- 4.04
- Debt to equityWhat is the debt to equity ratio? Debt to equity is a company's total debt divided by its shareholders' equity: how much it has borrowed for each dollar its owners have in the business.
- 1.07
- Piotroski scoreWhat is the Piotroski F-Score? The Piotroski F-Score rates a company's financial strength from 0 to 9: one point for each of nine tests of profit, debt and efficiency it passes.
- 8 / 9
- Altman Z-scoreWhat is the Altman Z-Score? The Altman Z-Score rolls five financial ratios into one number that signals a company's risk of bankruptcy: over 3 is safe, under 1.8 is distress.
- 2.19
Cash, debt and free cash flow
Cash and short-term investments Total debt Free cash flow
Medline ownershipWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- InstitutionsWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- 104.31%
- Institutional holders
- 425 (+95)
- Free floatWhat is free float? Free float is the part of a company's shares that anyone can buy and sell: all its shares minus those held by insiders, founders and owners of over 5%.
- 58.11%
Who owns the shares
Institutions 100.0% Others 0.0%
As of 30 Jun 2026
Shares free to trade
Free float 510.55M shares ·58.1% Closely held 368.11M shares ·41.9%
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Insider trading
| Quarter | Purchases | Sales | Shares acquired | Shares disposed of |
|---|---|---|---|---|
| Q4 2026 | 0 | 5 | 0.00 | 20.68M |
| Q2 2026 | 0 | 4 | 11.35M | 56.45M |
| Q1 2026 | 0 | 5 | 18.79M | 317.12M |
| Q4 2025 | 0 | 3 | 6.82M | 61.96M |
Shares outstanding
Basic shares Diluted shares Change in diluted shares
Source: Financial Modeling Prep
Title: Medline Inc
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Medline is the largest provider of medical-surgical products and supply chain solutions in the US. The company generates over 90% of its revenue domestically and serves some of the largest US health systems. Medline offers approximately 190,000 Medline-branded products across more than 250 product families-including front-line care, surgical solutions, and laboratory and diagnostics-as well as roughly 150,000 third-party products sourced from over 1,250 vendors. The company maintains prime vendor relationships with many customers, acting as the primary consolidated logistics partner for their medical-surgical needs. Medline has significant scale, supported by more than 30 manufacturing facilities and a fleet of over 2,000 owned delivery trucks. Medline went public in December 2025.